Talimogene laherparepvec: First in class oncolytic virotherapy

被引：248

作者：

Conry, Robert M. ^{[1
]}

Westbrook, Brian ^{[2
]}

McKee, Svetlana ^{[1
]}

Norwood, Timothy Graham ^{[2
]}

机构：

[1] Univ Alabama Birmingham, Med Div Hematol & Oncol, Birmingham, AL USA

[2] Univ Alabama Birmingham, Med, Birmingham, AL USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期

关键词：

Talimogene laherparepvec; oncolytic virus; melanoma; herpes simplex viral type I; granulocyte-macrophage colony-stimulating factor; granulomatous dermatitis; immune checkpoint blockade;

D O I：

10.1080/21645515.2017.1412896

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses.

引用

页码：839 / 846

页数：8

共 50 条

[1]

Fountzilas C., Patel S., Mahalingam D., Review: oncolytic virotherapy, updates and future directions, Oncotarget, 8, 20, pp. 102617-102639, (2017)

[2]

Russell S.J., Peng K.W., Oncolytic virotherapy: a contest between apples and oranges, Molecular Therapy, 25, 5, pp. 1107-1116, (2017)

[3]

Kohlhapp F.J., Kaufman H.L., Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy, Clin Cancer Res, 22, 5, pp. 1048-1054, (2015)

[4]

Williams B.R., PKR

[5]

a sentinel kinase for cellular stress, Oncongene, 18, pp. 6112-6120, (1999)

[6]

Farassati F., Yang A.D., Lee P.W., Oncogenes in Ras signaling pathway dictate host-cell permissiveness to herpes simplex virus 1, Nat Cell Biol, 3, pp. 745-750, (2001)

[7]

Smith K.D., Mezhir J.J., Bickenbach K., Veerapong J., Charron J., Posner M.C., Roizman B., Weichselbaum R.R., Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma (1) 34.5 mutants of herpes simplex virus 1, J Virol, 80, pp. 1110-1120, (2006)

[8]

Pansky A., Hildebrand P., Fasler-Kan E., Baselgia L., Ketterer S., Beglinger C., Heim M.H., Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha, In J Cancer, 85, pp. 720-725, (2000)

[9]

Zhang K.X., Matsui Y., Hadaschik B.A., Lee C., Jia W., Bell J.C., Fazli L., So A.I., Rennie P.S., Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death, Int J Cancer, 127, pp. 830-838, (2010)

[10]

He B., Gross M., Roizman B., The gamma (1) 34.5 proteins of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase, Proc Natl Acad Sci U S A, 94, pp. 843-848, (1997)

← 1 2 3 4 5 →